TNX-1700

Preclinical

Phase I

Phase II

Phase III

Gastric and Colorectal Cancers

Preclinical

TNX-1700 is a stabilized recombinant version of Trefoil Factor 2 (TFF2) and is being developed by Tonix as a biologic to treat gastric and colorectal cancers. TFF2 is a small, secreted protein, encoded by the TFF2 gene in humans that is expressed in gastrointestinal mucosa where it functions to protect and repair mucosa. TFF2 is also expressed at low levels in splenic immune cells and is now appreciated to have intravascular roles in spleen and in the tumor microenvironment. In gastric cancer, TFF2 is epigenetically silenced, and TFF2 is suggested to be protective against cancer development through several mechanisms.

Currently TNX-1700 is being evaluated in a study to assess its efficacy in converting anti-PD1 non-responsive tumors into anti-PD1 responsive tumors, primarily in colorectal cancer. Anti-PD-1 monotherapy was unable to evoke anti-tumor immunity in a model of colorectal cancer, but TFF2-CTP augmented the efficacy of anti-PD-1 therapy. (Source: Poster @ 2020 AACR Virtual Meeting II)

 

TNX-1700 is an investigational new biologic and has not been approved for any indication.